Streetbeat News

Stock Prices

URGN

Oppenheimer analyst Leland Gershell has maintained an Outperform rating on UroGen Pharma (NASDAQ:URGN) but has reduced the price target from $33 to $32.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:23 pm

CISO

CISO Global shares have risen following the announcement of their participation in the Microsoft Security Copilot Partner Private Preview.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:23 pm

QUIK

Oppenheimer analyst Martin Yang has maintained an Outperform rating on QuickLogic (NASDAQ:QUIK) and increased the price target from $10 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:22 pm

PDSB

Oppenheimer analyst Leland Gershell has maintained an Outperform rating on PDS Biotechnology (NASDAQ:PDSB) but has reduced the price target from $23 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:20 pm

PLUG

Plug Power, Inc. (NASDAQ:PLUG) is experiencing a rebound with shares trading higher, following a 40% drop after a disappointing Q3 earnings report and a 'going concern' warning. The stock rose 15% on Tuesday despite UBS analyst Manav Gupta lowering the price target from $15.5 to $5. The company is also facing significant short interest, with 24.08% of PLUG shares sold short. Trading volume has surged, with nearly 40 million shares traded compared to an average of over 25 million.

Portfolio Pulse from Erica Kollmann

November 15, 2023 | 6:18 pm

CSIQ

Oppenheimer analyst Colin Rusch has maintained an Outperform rating on Canadian Solar (NASDAQ:CSIQ) but has reduced the price target from $68 to $51.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:16 pm

ATRI

Atrion Corporation's stock is trading lower following the announcement of a year-over-year decline in its third-quarter financial results.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:15 pm

DAL

Delta Air Lines has projected that it will serve between 6.2 million and 6.4 million customers from November 17 to November 28, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:14 pm

IMVT

Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Immunovant (NASDAQ:IMVT) and increased the price target from $30 to $48 as reported on November 14, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 6:14 pm

SPRC

SciSparc Ltd (NASDAQ:SPRC) stock surged after announcing positive Phase IIa clinical trial results for SCI-110, a drug for treating agitation in elderly Alzheimer's patients. The trial met primary endpoints for tolerability and adverse events, showing potential to alleviate agitation without side effects. The stock's volume exceeded 10.55 million shares, far above the 100-day average of 1.181 million, with a small float of over 523 thousand shares. SPRC shares jumped 58% to $6.87.

Portfolio Pulse from Erica Kollmann

November 15, 2023 | 6:12 pm